三鑫醫療(300453.SZ)及子公司2020年度擬向銀行及其他金融機構申請貸款等方式使用融資額不超3億元
格隆匯3月27日丨三鑫醫療(300453.SZ)公佈,公司於2020年3月26日召開了第四屆董事會第二次會議,審議並通過了《關於2020年度融資計劃的議案》。
根據公司戰略發展規劃,為保證現金流量充足,滿足不斷擴展的經營模式,給公司和股東創造更多價值,公司及子公司2020年度擬通過向銀行及其他金融機構申請貸款等合法方式使用融資金額總計不超過3億元人民幣(融資額度可滾動使用),具體融資方式包括但不限於信用貸款、使用公司及子公司自有資產申請抵押貸款等,但公司發行可轉換公司債券等需要行政許可的除外。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.